Encouraging results on selective TK2 inhibitor in active PsA patients. ACR20 at week 16 of 53% and 63%, for low and high dose, compared to 32% placebo. NP, sinusitis, ha, rash most common AEs. Abst#L03 @RheumNow #ACR20 https://t.co/2UrOKFfnCL